Brief: New Nordic Healthbrands Q2 EBITDA Turns To Loss At SEK 6.3 Mln

New Nordic Healthbrands AB

29/07/2022 07:09

July 29 (Reuters) - New Nordic Healthbrands AB  NWND.ST :
    * H1 NET SALES SEK 254.0 MILLION VERSUS SEK 268.9 MILLION
YEAR AGO
    * NEW NORDIC HEALTHBRANDS AB (PUBL) SIX MONTHS REPORT
JANUARY -
JUNE 2022
    * Q2 NET SALES MSEK 130.7 (141.1)
    * Q2 EBITDA DECREASED TO MSEK -6.3 (11.2)
    * DUE TO CURRENT INTERNATIONAL GEOPOLITICAL AND ECONOMIC
SITUATION, WHICH WE BELIEVE WILL LAST WELL INTO 2023, WE ARE
TAKING STEPS TO REDUCE OUR MARKETING AND INNOVATION INVESTMENTS
TEMPORARILY
    * AS WELL AS WE ARE INTRODUCING A SHORTER MARKETING PLANNING
HORIZON TO BECOME MORE AGILE AND REACT QUICKER TO BOTH NEGATIVE
AND POSITIVE CHANGES IN WORLD AROUND US
    * WE EXPECT THAT REDUCTION IN INVESTMENTS DURING SECOND HALF
YEAR
WILL RESULT IN LOWER SALES IN SECOND HALF YEAR THAN IN FIRST
HALF YEAR
    * AS A RESULT OF CURRENT SITUATION, WE HAVE DECIDED TO
POSTPONE
OUR APPLICATION FOR LISTING OF OUR SHARES ON NASDAQ STOCKHOLM
MAIN MARKET
    * POSTPONMENT OF LISTING;  SO FAR UNTIL END OF 2023.
    * WE PLAN TO FINANCE GROWTH BEYOND 2022 OURSELVES.

Source text for Eikon:  ID:nBQN5xrdLp 
Further company coverage:  NWND.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))